These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2005-005670-71 Dose-finding and Phase II study of the Combination of Bevacizumab rhuMAb VEGF plus low- dose Immunotherapy and Chemotherapy in patients with metastatic Renal Cell Cancer. bad-data
Ongoing, reported early 2005-005770-72 RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA MRCC A GOIRC PHASE II STUDY not-yet-due
Ongoing 2006-003929-83 Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. not-yet-due
Completed, but no date 2006-004009-24 Randomized phase II study of pemetrexed versus pemetrexed and carboplatin as second line chemotherapy in advanced non-small-cell lung cancer (NSCLC). bad-data
Completed, but no date 2007-004693-34 Multicenter, phase II study of chemotherapy with dose-dense modified TCF in locally advanced or metastatic gastric cancer. bad-data
Not reported 2007-007949-13 Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC) 2016-05-31 due-trials
Ongoing 2008-000528-22 Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overe... not-yet-due
Ongoing 2008-000928-71 “TWIST”. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008 not-yet-due
Ongoing 2008-008387-27 Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity. not-yet-due
Completed, but no date Terminated 2009-013472-41 A GOIRC Phase II randomized trial of an oral chemotherapy combination of Capecitabine plus Vinorelbine and their sequential single agent use in Metastatic Breast Cancer bad-data
Not reported 2009-016962-10 First Line Dose-Dense Chemotherapy With Docetaxel, Cisplatin, Folinic Acid and 5- Fluorouracil plus Panitumumab in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastro-Esophage... 2014-09-08 due-trials
Ongoing 2009-017094-38 Gene expression as predictive markers of outcome in non-small cell lung cancer patients (stage IIIB with pleural effusion and stage IV) treated with chemotherapy. Phase II trial of GOIRC. not-yet-due
Completed, but no date 2012-003505-10 Phase II study of Eribulin in combination with Gemcitabine for the First-line Treatment of Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer. Protocol ERIGE. Studio di fas... bad-data
Ongoing 2014-003951-72 Phase II randomized multicenter study of Everolimus as maintenance therapy for metastatic neuroendocrine carcinoma with pulmonary or gastroenteropancreatic origin. Studio multicentrico randomizzat... not-yet-due
Completed, but no date 2016-000408-27 Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC (NABSTER trial) Studio di Fase II di Nab-paclitaxel nel carcinoma polmonare a piccole cellule (SCLC) recidivato sensibile ... bad-data
Completed, but no date 2016-000435-41 Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients with Operable or Locally Advanced/Inflammatory HER2-po... bad-data
Ongoing 2016-001132-36 A double-blind, placebo controlled, randomized multicenter Phase II Study evaluating Gemcitabine with or without Ramucirumab as II line treatment for advanced malignant pleural mesothelioma Studio ... not-yet-due
Ongoing 2016-003030-24 “An open-label, randomized phase III study of Early switch maintenance vs DElayed second-line Nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line... not-yet-due
Ongoing 2016-003031-38 Phase II randomized study of maintenance Regorafenib vs Placebo in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metastat... not-yet-due
Completed, but no date 2016-003032-20 Nivolumab plus Stereotactic Body Radiotherapy (SBRT) in II and III line of Patients With Metastatic Renal Cell Carcinoma (mRCC). Nivolumab plus Stereotactic Body Radiotherapy (SBRT) in II and III l... bad-data
Ongoing 2017-004500-22 Phase II multicentre trial of perioperative chemotherapy in operable patients with gastric cancer (PERISCOPE trial) PERISCOPE: studio di fase II multicentrico di chemioterapia perioperatoria nel ca... not-yet-due
Ongoing 2018-002607-34 Phase II, open-label study of atezolizumab in a CoHort of pretreated, Advanced Non-small cell lung cancer (NSCLC) patients with rare histologiCal subtypEs – CHANCE trial Studio di fase II, in apert... not-yet-due
Ongoing 2018-002893-38 Phase II Study on NIVolumab in combination with FOLFOXIRI/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer RASm/BRAFm patients Studio di fase II con Nivolumab in combinazione co... not-yet-due
Ongoing 2018-003833-14 A Phase IV study on impact of Edoxaban treatment in Italian cancer patients with venous thromboembolism (EDOI Cancer Study) during antineoplastic therapy Studio di fase IV sull’impatto del trattame... not-yet-due
Ongoing 2019-003798-25 A phase II, single arm study of CarbopLatin plus Etoposide with Bevacizumab and Atezolizumab in patients with exTEnded-disease small-cell lung cancer (SCLC) – CeLEBrATE trial Studio di fase II, a b... not-yet-due
Ongoing 2019-004357-86 A Phase II open-label multicentreTrial of first-line Oxaliplatin-based chemotherapy combined with ABP 980 (Biosimilar Trastuzumab) in patients with advanced Gastric or gastro-Esophageal juncTion (GEJ)... not-yet-due
Ongoing 2020-003432-25 Phase II, open-label, single-arm, multicenter study to assess the activity and safety of ALectinib as NEO-adjuvant therapy in patients with anaplastic lymphoma kinase-positive (ALK+) locally advanced ... not-yet-due
Ongoing 2020-003762-39 PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION Studio di fase III con atezolizumab verso placebo in pazienti con mesotel... not-yet-due
Ongoing 2020-005792-12 Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC) Studio Pilota... not-yet-due
Ongoing 2020-005942-41 A multicenter phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neur... not-yet-due
Ongoing 2021-003305-21 First-line Osimertinib plus Consolidation Radiotherapy compared with Osimertinib alone in oligometastatic NSCLC EGFR mutated patients: the randomized phase II OCRa trial GOIRC-06-2019 Studio random... not-yet-due